CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 200 target
Drug / intervention
Prednisone,Vincristine, Cyclophosphamide +5 moredrug
Likely dose
Prednisone,Vincristine, Cyclophosphamide 45mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02405676
NCT02405676Phase 3ActiveUpdate OverdueUpdated 3mo ago · Completion was 30mo ago
Enrollment Stalled
CompareCT.gov

Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China

Children's Cancer Group, China·interventional·Posted Apr 1, 2015·Updated Mar 19, 2026

In Brief

A Phase 3 clinical trial evaluating Prednisone,Vincristine, Cyclophosphamide, Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone, and 4 other interventions for Mature B-cell Non-Hodgkin Lymphoma. Active but no longer recruiting, targeting 200 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

The purpose of this study is to test whether adding 4 injections of rituximab and increasing the intensity of chemotherapy regimens in advanced patients can improve the EFS compared with the historical study CCCG-NHL-2010.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMature B-cell Non-Hodgkin Lymphoma
CountriesChina
CollaboratorsTongji Hospital, Nanjing Children's Hospital, West China Second University Hospital, Xiangya Hospital of Central South University, Qilu Hospital of Shandong University, Children's Hospital of Soochow University, Tianjin Medical University Cancer Institute and Hospital

Timeline

Phase 3Active
2015201620172018201920202021202220232024202520262027202820292030
First PostedApr 1, 2015
Enrollment StartJan 1, 2015
Primary CompletionDec 31, 2023
Study CompletionDec 1, 2029
TodayJul 1, 2026
Enrollment to primary: 9 yearsPosted 11.3 years ago

Interventions

Prednisone,Vincristine, Cyclophosphamidedrug

Prednisone 45mg/m2, D1\~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;

Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisonedrug

Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisonedrug

Ifosphamide 1.2g/m2, D1\~5; Etoposide, 60mg/m2, D3\~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1;

Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisonedrug

Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2\~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisonedrug

Ifosphamide 1.2g/m2, D1\~5; Etoposide, 100mg/m2, D3\~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1\~7;Intrathecal injection, D1,8;

Rituximabdrug

375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;